Abstract:Gene therapy is a promising therapeutic approach for treating life-threatening disorders. Despite the clinical improvements observed with gene therapy, immune responses either innate or adaptive against the vector used for gene delivery, can affect treatment efficacy and lead to adverse reactions. Thrombotic microangiopathy (TMA) is a thrombosis with thrombocytopenia syndrome (TTS) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and small vessel occlusion known to be elicited by several drugs, that has been recently reported as an adverse event of adeno-associated virus (AAV)-based gene therapy. TMA encompasses a heterogenous group of disorders, its classification and underlining mechanisms are still uncertain, and still lacks validated biomarkers. The identification of predictors of TMA, such as vector dose and patient characteristics, is a pressing need to recognize patients at risk before and after AAV-based gene therapy administration. This review aims to explore the literature on TMA associated with AAV-based gene therapy in the larger context of TMA (i.e., hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and other drug-related TMAs). Considering the wide attention recently gained by another TTS associated with a non-gene therapy viral platform (adenovirus, AV COVID-19 vaccine), namely vaccine-induced immune thrombocytopenia and thrombosis (VITT), AAV gene therapy–related TMA mechanisms will be discussed and differentiated from those of VITT to avoid recency bias and favor a correct positioning of these two recently emerged syndromes within the heterogenous group of drug-related TTS. Finally, the review will discuss strategies for enhancing the safety and optimize the management of AAV-based gene therapy that is emerging as an efficacious therapeutic option for disparate, severe, and often orphan conditions. All authors conceived the project, wrote, edited, and revised the manuscript critically. All authors approved the final version of the manuscript. * These authors share senior authorship. Received: 02 February 2024 Accepted: 04 August 2024 Accepted Manuscript online: 11 September 2024 Article published online: 03 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Stuttgart · New York

Thrombotic microangiopathy as an emerging complication of viral vector-based gene therapy.

Emerging Thrombotic Disorders Associated with Virus-Based Innovative Therapies: From VITT to AAV Gene Therapy–Related Thrombotic Microangiopathy

The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution

Immune Responses to Viral Gene Therapy Vectors

Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges

Drug-induced liver injury related to gene therapy: A new challenge to be managed

Clinical and Translational Landscape of Viral Gene Therapies

Viral vector‐based gene therapies in the clinic

Current Clinical Applications of In Vivo Gene Therapy with AAVs

State of Gene Therapy for Monogenic Cardiovascular Diseases

Complement system response to adeno-associated virus (AAV) vector gene therapy.

Viral vectors for therapy of neurologic diseases

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Viral vector platforms within the gene therapy landscape

Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Current status and prospects of viral vector-based gene therapy to treat kidney diseases

Hepatitis after gene therapy, what are the possible causes?

A primer to gene therapy: Progress, prospects, and problems

Neurosurgical gene therapy for central nervous system diseases

Gene Therapy Leaves a Vicious Cycle